GlassScriptPhysician profile
Christina Adams
NPI 1114120169
$3,996.27
in general payments reported to CMS, 2019-2025
36 companies · $798 in 2025
The $798 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $560 · 2020: $218 · 2021: $767 · 2022: $405 · 2023: $462 · 2024: $786 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $743.53 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $344.97 | 2019-2024 | Veozah |
| Pfizer INC. | $329.72 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.94 | 2019-2025 | Jardiance |
| Amgen INC. | $286.08 | 2019-2024 | Evenity, Prolia, Repatha |
| Abbvie INC. | $268.22 | 2021-2025 | Vraylar, Qulipta |
| Abbott Laboratories | $201.73 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $190.44 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Melinta Therapeutics, LLC | $147.35 | 2019-2020 | |
| Glaxosmithkline, LLC. | $143.16 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $109.71 | 2019-2025 | |
| Esperion Therapeutics, INC. | $93.73 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $91.33 | 2019-2023 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.43 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $87.35 | 2019-2023 | Dificid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $65.20 | 2020-2021 | |
| Shield Therapeutics INC | $58.45 | 2022-2025 | |
| Dexcom, INC. | $54.84 | 2023-2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $53.46 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $36.38 | 2023-2025 | |
| Daiichi Sankyo INC. | $32.82 | 2019 | |
| Nevro Corp. | $32.58 | 2024 | Senza |
| Corcept Therapeutics | $29.41 | 2024 | Korlym |
| Boston Scientific Corporation | $23.54 | 2025 | Intracept |
| Medtronic Minimed, INC. | $21.95 | 2019 | |
| Amarin Pharma, INC. | $20.31 | 2019 | |
| Dynavax Technologies Corporation | $19.14 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.68 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $17.82 | 2020 | |
| Optinose US, INC. | $15.31 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $14.93 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.74 | 2021 | |
| Exact Sciences Corporation | $14.60 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $12.64 | 2021 | |
| Eisai INC. | $12.50 | 2021 | |
| Kci USA, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.